Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model
Antimicrobial Agents and Chemotherapy
American Society for Microbiology
ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P <= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.
Iyer, R.P., A. Roland, Y. Jin, S. Mounir, B. Korba, J.G. Julander, and J.D. Morrey 2004. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model Antimicrobial Agents and Chemotherapy 48(6): 2318-2320.